27 Sep 2022 07:00
Yourgene Health plc
("Yourgene" or the "Company")
AGM statement
Manchester, UK - 27 September 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, will be holding its Annual General Meeting ("AGM") at 2:00pm today.
At the meeting, Dr John Brown CBE, Non-executive Chairman, will make the following statement:
'It is a pleasure to be at my first AGM as Chairman of Yourgene after 3 years on the Board as a Non-executive Director. I would like to thank my predecessor Adam Reynolds for his contribution to making Yourgene the exciting business it is today. The business is a growing force in genomic testing and is addressing growth opportunities in non-invasive prenatal testing, oncology, reproductive health and infectious disease, with an increasing presence in key overseas geographies including North America, Europe and Asia.
We continue to see the core business performing at pre-pandemic growth levels.
The team has done a great job during the pandemic and, having come out the other side, is now both better resourced and equipped. With solid progress being made in the first half, we are now focused on a number of pipeline opportunities that will support growth in the second half and underpin next year's performance. The Board looks forward to updating the market at the time of our interim results release in due course.
Yourgene is distinguished by its breadth of high growth value propositions, some of which represent near-term commercial opportunities to build market share, while others reflect truly accretive prospects to create longer-term value, including through geographic expansion and new product or service launches.
I look forward to working with the Board, shareholders, and the management team to chart our way to delivering the best mix of these near and long term opportunities.'
After the formal AGM proceedings, Lyn Rees, CEO, will provide shareholders with a short business update ahead of the onsite Investor Open Day later in the afternoon. The Open Day is to be held at the Company's new headquarters in Skelton House, Manchester Science Park, M15 6SH. This is now the sole UK business premise for Yourgene and all other locations including Citylabs have moved to the new site.
The AGM will be available as a hybrid event via the Investor Meet Company platform. Investors can sign up to Investor Meet Company for free and register for the Yourgene Health meeting via: https://www.investormeetcompany.com/yourgene-health-plc/register-investor.
The presentation recording and responses to investor questions will be made available on the Investor Meet Company platform at the earliest opportunity.
Yourgene Health plc Lyn Rees, Chief Executive Officer | Tel: +44 (0)161 669 8122 investors@yourgene-health.com | ||
Barry Hextall, Chief Financial Officer | |||
Joanne Cross, Director of Marketing | |||
| |||
Cairn Financial Advisers LLP (NOMAD) | Tel: +44 (0)20 7213 0880 | ||
Liam Murray / James Caithie / Ludovico Lazzaretti | |||
| |||
Singer Capital Markets (Corporate Broker) | Tel: +44 (0)20 7496 3000 | ||
Aubrey Powell / Tom Salvesen / George Tzimas | |||
| |||
Walbrook PR Ltd (Media and Investor Relations) | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com | ||
Paul McManus / Lianne Applegarth Alice Woodings | Mob: 07980 541 893 / Mob: 07584 391 303 / Mob: 07407 804 654 | ||
About Yourgene Health plc
Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.
The Yourgene Genomic Services team works with healthcare professionals, researchers and pharmaceutical organisations to support and accelerate scientific advances in genomic medicine. The division's specialist services guide decisions about abnormalities, hereditary risk and treatment in addition to providing novel insights in research and discovery. Accredited clinical services are provided in Oncology and Reproductive Health within the UK and worldwide. The team of scientific experts offer consultative services to help guide partners in selecting the right technology and approach for their applications.
In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.